Safety profile of lasmiditan in patients with migraine in an Asian population.

Author: HirataKoichi, KhannaRashna, KomoriMika, MatsumoriYasuhiko, OzekiAkichika, TanjiYuka

Paper Details 
Original Abstract of the Article :
MONONOFU, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of Japanese patients with migraine, was pivotal for lasmiditan approval in Japan. However, treatment-emergent adverse events (TEAEs) were more common than in global studies. A detailed safety profile would assist pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1080/14740338.2022.2087630

データ提供:米国国立医学図書館(NLM)

Safety Profile of Lasmiditan in Migraine Patients: An Asian Perspective

The treatment of [migraine] is a complex and often challenging journey, with patients seeking effective and safe medications to manage their symptoms. This study focuses on the safety profile of [lasmiditan] in an Asian population, specifically in Japan. The researchers, like skilled explorers venturing into a new territory, meticulously evaluated the safety of lasmiditan in a Japanese patient population, providing valuable insights into its potential side effects.

Navigating the Safety Landscape of Lasmiditan: An Asian Perspective

This study, like a detailed map of a newly discovered desert, provides a comprehensive understanding of the safety profile of lasmiditan in an Asian population. The authors' findings, like a clear path through the sand, highlight that while lasmiditan is generally well-tolerated, it may be associated with a higher incidence of treatment-emergent adverse events (TEAEs) compared to global studies. This research, like a well-equipped caravan, provides clinicians with valuable knowledge to navigate the potential risks and benefits of lasmiditan therapy in Asian patients.

A Personalized Approach to Migraine Management: Considering Geographic Differences

This study, like a compass guiding travelers through diverse landscapes, emphasizes the importance of considering geographic differences in the safety and efficacy of medications. The authors' findings highlight the need to tailor treatment strategies to the unique characteristics of different patient populations. This research, like a beacon of hope, shines a light on the need for more culturally sensitive and geographically relevant clinical trials to better understand the impact of medications on diverse populations.

Dr.Camel's Conclusion

This study provides valuable insights into the safety profile of lasmiditan in an Asian population, specifically in Japan. The findings underscore the importance of considering geographic differences in the safety and efficacy of medications. This research, like a well-stocked caravan, equips clinicians with the knowledge and tools to navigate the potential risks and benefits of lasmiditan therapy in Asian patients.

Date :
  1. Date Completed 2023-02-24
  2. Date Revised 2023-02-24
Further Info :

Pubmed ID

35736027

DOI: Digital Object Identifier

10.1080/14740338.2022.2087630

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.